Abdera Therapeutics

Abdera Therapeutics is a biopharmaceutical company leveraging antibody engineering to design and develop novel precision radiopharmaceuticals for cancer. Abdera's RadioOptimized Vector Engineering (ROVEr™) platform enables the company to design potential best-in-class therapies for clinically validated and novel targets, delivering potent radioisotopes that emit alpha or beta particles to selectively destroy cancer cells. Abdera's lead program focuses on utilizing DLL3 for the treatment of small cell lung cancer and other solid tumors.